Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HB-adMSCs in Juvenile Idiopathic Arthritis
NCT06623240Phase 2Withdrawn
- Sponsor
- Hope Biosciences
- Start
- Jan 2026
- Primary completion
- Jan 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic HB-adMSCs in juvenile idiopathic arthritis (JIA) (3 cohorts), sponsored by Hope Biosciences. Primary endpoints: Treatment-Emergent Adverse Events at 72 weeks, Serious Adverse Events at 72 weeks and 8 more. Planned start Jan 2026; status: withdrawn.
02
Drugs
allogeneic HB-adMSCs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT06623240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623240.